According to the American Society of Hematology (ASH), findings from phase III of the CHRONOS-3 trial testing a combination therapy using copanlisib and rituximab reduced the risk of progression or death by 48% compared with rituximab alone.
The study was open to participants who had relapsed Indolent B-cell Non-Hodgkin’s Lymphoma, including follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia, and marginal zone lymphoma.
Copanlisib is a PI3K inhibitor which is currently approved as a stand-alone therapy for relapsed follicular lymphoma. Rituximab is a chimeric monoclonal antibody that targets CD20. It’s used to treat a number of cancers and ailments, including B-cell Non-Hodgkin’s Lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
For more details on the results presented to ASH, see the online article here.
AGSchreibman.com 